|
|
???tair.name??? >
???browser.page.title.author???
|
"hatano e"???jsp.browse.items-by-author.description???
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
| 國家衛生研究院 |
2024-08-28 |
Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab
|
Shen, YC;Liu, TH;Nicholas, A;Soyama, A;Yuan, CT;Chen, TC;Eguchi, S;Yoshizumi, T;Itoh, S;Nakamura, N;Kosaka, H;Kaibori, M;Ishii, T;Hatano, E;Ogawa, C;Naganuma, A;Kakizaki, S;Cheng, CH;Lin, PT;Su, YY;Chuang, CH;Lu, LC;Wu, CJ;Wang, HW;Rau, KM;Hsu, CH;Lin, SM;Huang, YH;Hernandez, S;Finn, RS;Kudo, M;Cheng, AL |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
Showing items 1-3 of 3 (1 Page(s) Totally) 1 View [10|25|50] records per page
|